Agomelatine in depression

Expert Opinion on Drug Safety

Volumn 12, Issue 6, 2013, Pages 873-880

  Smeraldi, Enrico ^a   Delmonte, Dario ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

Agomelatine; Antidepressant; Chronobiology; Circadian rhythms; Major depression; Melatonine; Mood disorder

Indexed keywords

AGOMELATINE; ALCOHOL; ANTIDEPRESSANT AGENT; BENZODIAZEPINE; BRAIN DERIVED NEUROTROPHIC FACTOR; CIPROFLOXACIN; CYTOCHROME P450; FLUCONAZOLE; FLUOXETINE; FLUVOXAMINE; LITHIUM; MELATONIN 1 RECEPTOR; MELATONIN 2 RECEPTOR; MESSENGER RNA; PAROXETINE; SEROTONIN 2C ANTAGONIST; SEROTONIN 2C RECEPTOR; SEROTONIN UPTAKE INHIBITOR; THEOPHYLLINE; VALPROIC ACID; VALPROMIDE; VENLAFAXINE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BIPOLAR DISORDER; BIPOLAR I DISORDER; BIPOLAR II DISORDER; BLURRED VISION; BODY WEIGHT; CIRCADIAN RHYTHM; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL (TOPIC); CONSTIPATION; DEPRESSION; DIARRHEA; DIZZINESS; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MARKETING; DRUG MECHANISM; DRUG OVERDOSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; GASTROINTESTINAL DISEASE; HAMILTON SCALE; HUMAN; HYPERTRANSAMINASEMIA; HYPOMANIA; INSOMNIA; MAJOR DEPRESSION; MENTAL DISEASE; MOOD DISORDER; NAUSEA; NEUROTRANSMISSION; NONHUMAN; PARESTHESIA; PHASE 3 CLINICAL TRIAL (TOPIC); POSTMARKETING SURVEILLANCE; PSEUDOVERTIGO; PSYCHOPHARMACOLOGY; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHINOPHARYNGITIS; SEASONAL AFFECTIVE DISORDER; SEXUAL DYSFUNCTION; SIDE EFFECT; SINGLE DRUG DOSE; SINUSITIS; SOMNOLENCE; TREATMENT RESPONSE; WEIGHT GAIN; XEROSTOMIA;

ACETAMIDES; ANIMALS; ANTIDEPRESSIVE AGENTS; BIPOLAR DISORDER; DEPRESSIVE DISORDER, MAJOR; HUMANS; MELATONIN; SEROTONIN 5-HT2 RECEPTOR ANTAGONISTS; TREATMENT OUTCOME;

EID: 84886614448     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2013.828690     Document Type: Article

References (64)

1. World Health Organization. The world health report 2001-mental health: New understanding, new hope. World Health Organization; Geneva; 2001
2. Kessler RC, Berglund P, Demler O, et al. National Comorbidity Survey Replication. The epidemiology of major depressive disorder: Results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003;289:3095-105
3. Kessler RC, Demler O, Frank RG, et al. Prevalence and treatment of mental disorders, 1990 to 2003. N Engl J Med 2005;352(24):2515-23
4. Parikh SV, Lam RW; CANMAT Depression Work Group. Clinical guidelines for the treatment of depressive disorders, I. Definitions, prevalence, and health burden. Can J Psychiatry 2001;46:13S-20S
5. Frank E, Prien RF, Jarrett RB, et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Arch Gen Psychiatry 1991;48(9):851-5
6. Kennedy SH, Eisfeld BS, Meyer JH, Bagby RM. Antidepressants in clinical practice: Limitations of assessment methods and drug response. Hum Psychopharmacol 2001;16(1):105-14
7. Kirchheiner J, Bertilsson L, Bruus H, et al. Individualized medicine - implementation of pharmacogenetic diagnostics in antidepressant drug treatment of major depressive disorders. Pharmacopsychiatry 2003;36:S235-43
8. Joyce PR, Mulder RT, Luty SE, et al. A differential response to nortriptyline and fluoxetine in melancholic depression: The importance of age and gender. Acta Psychiatr Scand 2003;108(1):20-3
9. Stahl SM, Pradko JM, Haight BR, et al. A review of the neuropharmacology of bupropion, a dual norepinephrine and dopamine reuptake inhibitor. Prim Care Companion J Clin Psychiatry 2004;6:159-66
10. Pandi-Perumal SR, Srinivasan V, Cardinali DP, et al. Could agomelatine be the ideal antidepressant? Expert Rev Neurother 2006;6:1595-607
11. Rosenbaum JF. Depression and its subtypes: A treatment update. Conclusion. J Clin Psychiatry 1998;59:37-8
12. Vanderkooy JD, Kennedy SH, Bagby RM. Antidepressant side effects in depression patients treated in a naturalistic setting: A study of bupropion, moclobemide, paroxetine, sertraline, and venlafaxine. Can J Psychiatry 2002;47(2):174-80
13. Zajecka JM. Augmentation strategies to increase antidepressant tolerability. J Clin Psychiatry 2007;68:23-7
14. Zajecka JM. Clinical issues in long-term treatment with antidepressants. J Clin Psychiatry 2000;61:20-5
15. Stahl SM. Novel mechanism of antidepressant action: Norepinephrine and dopamine disinhibition (NDDI) plus melatonergic agonism. Int J Neuropsychopharmacol 2007;10:575-8
16. San L, Arranz B. Agomelatine: A novel mechanism of antidepressant action involving the melatonergic and serotonergic system. Eur Psychiatry 2008;23:396-402
17. Zupanic M, Guilleminault C. Agomelatine: A preliminary review of a new antidepressant. CNS Drugs 2006;20:981-92
18. Loo H, Hale A, D'haenen H. Determination of the dose of agomelatine, a melatonergic agonist and selective 5HT2c antagonistic, in the treatment of major depressive disorder: A placebo-controlled dose range study. Int Clin Psychopharmacol 2002;17:239-47
19. Kennedy SH, Emsley RA. Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. Eur Neuropsychopharmacol 2006;16(2):93-100
20. Olie JP, Kasper S. Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2c antagonistic properties in major depressive disorder. Int J Neuropsychol Pharmacol 2007;10(5):661-73
21. Hindmarch I, Kimber S, Cockle SM. Abrupt and brief discontinuation of antidepressant treatment: Effects on cognitive function and psychomotor performance. Int Clin Psychopharmacol 2000;15(6):305-18
22. Kasper S, Hamon M. Beyond the monoaminergic hypothesis: Agomelatine, a new antidepressant with an innovative mechanism of action. World J. Biol Psychiatry 2009;1:1-11
23. Masand PS, Gupta S. Selective serotonin-reuptake inhibitors: An update. Harv Rev Psychiatry 1999;7(2):69-84
24. Anderson IM. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: A meta-analysis of efficacy and tolerability. J Affect Disord 2000;58(1):19-36
25. Servier Laboratories. Valdoxan. Available from: Http://www.valdoxan.com/ index. php/v aldoxan-package-leafletinformationfor- the-user/ [Accessed 3 May 2011]
26. Srinivasan V, Pandi-Perumal SR, Trakht I, et al. Pathophysiology of depression: Role of sleep and the melatonergic system. Psychiatry Res 2009;165(3):201-14
27. Van Reeth O, Olivares E, Zhang Y, et al. Comparative effects of a melatonin agonist on the circadian system in mice and Syrian hamsters. Brain Res 1997;762(1-2):185-94
28. Svestka J. Sleep deprivation therapy. Neuro Endocrinol Lett 2008;29(Suppl 1):65-92
29. Grassi-Zucconi G, Semprevivo M, Mocaer E, et al. Melatonin and its new agonist S-20098 restore synchronized sleep fragmented by experimental trypanosome infection in the rat. Brain Res Bull 1996;39(2):63-8
30. Weibel L, Turek FW, Mocaer E, Van Reeth O. A melatonin agonist facilitates circadian resynchronization in old hamsters after abrupt shifts in the light-dark cycle. Brain Res 2000;880(1-2):207-11
31. Racagni G, Riva MA, Molteni R, et al. Mode of action of agomelatine: Synergy between melatonergic and 5-HT(2C receptors. World J Biol Psychiatry 2011;12:574-87
32. Pompili M, Serafini G, Innamorati M, et al. Agomelatine, a novel intriguing antidepressant option enhancing neuroplasticity: A critical review. World J Biol Psychiatry 2013. [Epub ahead of print]
33. Millan MJ, Gobert A, Lejeune F, et al. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther 2003;306(3):954-64
34. Hanoun N, Mocae?r E, Boyer PA, et al. Differential effects of the novel antidepressant agomelatine (S 20098 versus fluoxetine on 5-HT1A receptors in the rat brain. Neuropharmacology 2004;47(4):515-26
35. Millan MJ, Gobert A, Rivet JM, et al. Mirtazapine enhances frontocortical dopaminergic and cortico limbic adrenergic but not serotonergic transmission by blockade of alpha-2 adrenergic and serotonergic 2c receptors; a comparison with citalopram. Eur J Neurosci 2000;12:1079-95
36. Duman RS, Monteggia LM. A neurotrophic model for stress-related mood disorders. Biol Psychiatry 2006;59(12):1116-27
37. Banasr M, Soumier A, Hery M, et al. Agomelatine, a new antidepressant, induces regional changes in hippocampal neurogenesis. Biol Psychiatry 2006;59(11):1087-96
38. Conboy L, Tanrikut C, Zoladz PR, et al. The antidepressant agomelatine blocks the adverse effects of stress on memory and enables spatial learning to rapidly increase neural cell adhesion molecule (NCAM) expression in the hippocampus of rats. Int J Neuropsychopharmacol 2009;12(3):329-41
39. Landolt HP, Meier V, Burgess HJ, et al. Serotonin-2 receptors and human sleep: Effect of a selective antagonist on EEG power spectra. Neuropsychopharmacology 1999;21(3):455-66
40. Skene DJ, Arendt J. Human circadian rhythms: Physiological and therapeutic relevance of light and melatonin. Ann Clin Biochem 2006;43:344-53
41. Kalsbeek A, La Fleur S, Van Heijningen C, Buijs RM. Suprachiasmatic GABAergic inputs to the paraventricular nucleus control plasma glucose concentrations in the rat via sympathetic innervation of the liver. J Neurosci 2004;24(35):7604-13
42. Paula-Lima AC, Louzada PR, De Mello FG, Ferreira ST. Neuroprotection against Abeta and glutamate toxicity by melatonin: Are GABA receptors involved? Neurotox Res 2003;5(5):323-7
43. Wan Q, Man HY, Liu F, et al. Differential modulation of GABAA receptor function by Mel1a and Mel1b receptors. Nat Neurosci 1999;2(5):401-3
44. Eser D, Baghai TC, Moller HJ. Evidence of agomelatine's antidepressant efficacy: The key points. Int Clin Psychopharmacol 2007;22(Suppl 2):S15-19
45. Wagner J, Wagner ML, Hening WA. Beyond benzodiazepines: Alternative pharmacologic agents for the treatment of insomnia. Ann Pharmacother 1998;32(6):680-91
46. Millan MJ, Brocco M, Gobert A, Dekeyne A. Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: Role of 5-HT2C receptor blockade. Psychopharmacology (Berl ;177(4):448-58
47. Kasper S, Hajak G, Wulff K, et al. Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: A randomized, double blind comparison with sertraline. J Clin Psychiatry 2010;71(2):109-20
48. Hale A, Corral RM, Mencacci C, et al. Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: A randomized double-blind study. Int Clin Psychopharmacol 2010;25(6):305-14
49. Lemoine R, Guilleminault C, Alvarez E. Improvement in subjective sleep in major depressive disorder with a novel antidepressant agomelatine: Randomized, double- blind comparison with venlafaxine. J Clin Psychiatry 2007;68:1723-32
50. Pjrek E, Winkler D, Konstantinidis A, et al. Agomelatine in the treatment of seasonal affective disorder. Psychopharmacology (Berl ;190:575-9
51. Calabrese JR, Guelfi JD, Perdrizet-Chevallier C; Agomelatine Bipolar study group. Agomelatine adjunctive therapy for acute bipolar depression: Preliminary open data. Bipolar Disord 2007;6:628-35
52. Fornaro M, McCarthy MJ, De Berardis D, et al. Adjunctive agomelatine therapy in the treatment of acute bipolar II depression: A preliminary open label study. Neuropsychiatr Dis Treat 2013;9:243-51
53. Goodwin GM, Emsley R, Rembry S, et al. Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: A 24-week randomized, double-blind, placebocontrolled trial. J Clin Psychiatry 2009;70:1128-37
54. Agomelatine: A review of adverse effects. Prescrire Int 2013;22(136):70-1
55. Kennedy SH, Rizvi SJ. Agomelatine in the treatment of major depressive disorder: Potential for clinical effectiveness. CNS Drugs 2010;24(6):479-99
56. McAllister-Williams RH, Baldwin DS, Haddad PM, Bazire S. The use of antidepressants in clinical practice: Focus on agomelatine. Hum Psychopharmacol Clin Exp 2010;25:95-102
57. Kennedy SH, Rizvi S, Fulton K, Rasmussen J. A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR. J Clin Psychopharmacol 2008;28(3):329-33
58. Montejo AL, Prieto N, Terleira A, et al. Better sexual acceptability of agomelatine (25 and 50 mg) compared with paroxetine (20 mg) in healthy male volunteers. An 8-week, placebo-controlled study using the PRSEXDQ-SALSEX scale. J Psychopharmacol 2010;24(1):111-20
59. Sapetti A. Agomelatine: An antidepressant without deterioration of sexual response. J Sex Marital Ther 2012;38:190-7
60. Zajecka J, Schatzberg A, Stahl S, et al. Efficacy and safety of agomelatine in the treatment of major depressive disorder: A multicenter, randomized, double-blind, placebo-controlled trial. J Clin Psychopharmacol 2010;30(2):135-44
61. Montgomery SA, Kennedy SH, Burrows GD, et al. Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: A randomized, double-blind, placebo-controlled discontinuation study. Int Clin Psychopharmacol 2004;19(5):271-80
62. Llorca PM. The antidepressant agomelatine improves the quality of life of depressed patients: Implications for remission. J Psychopharmacol 2010;24:21
63. Kaspera S, Corrubleb E, Halee A, et al. Antidepressant efficacy of agomelatine versus SSRI/SNRI: Results from a pooled analysis of head to-head studies without a placebo control. Int Clin Psychopharmacol 2013;28:12-19
64. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: A multiple-treatments meta-analysis. Lancet 2009;373(9665):746-58